Glucocorticoids are crucial in the initiation and consolidation of the stress response. Patients with active Cushing’s syndrome (CS) are exposed to excessive endogenous glucocorticoid levels. In these patients, psychopathology is often being observed. The most common co-morbid disorder is major depression, but to a lesser extent mania and anxiety disorders have also been reported. A severe clinical presentation of CS often also includes depression. Reduction of glucocorticoid synthesis or action, either with metyrapone, ketoconazole, or mifepristone, rather than treatment with antidepressant drugs, is generally successful in relieving depressive symptoms, as well as other disabling symptoms. Following successful surgical treatment of hypercortisolism, both physical and psychiatric signs and symptoms improve substantially. However, it appears that patients do not completely return to their premorbid level of functioning and persistent impairment of quality of life and cognitive function has been reported despite long-term cure. At present, it is not clear whether, and to which extent, psychopathology still affects general well-being after long-term cure of CS.

Keywords:
Cushing’s syndrome, Treatment, Depression, Mania, Psychopathology
1.
de Kloet ER, Joëls M, Holsboer F: Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005;6:463–475.
2.
Starr AM: Personality changes in Cushing’s syndrome. J Clin Endocrinol Metab 1952;12:502–505.
3.
Sablowski N, Pawlik K, Ludecke DK, Herrmann HD: Aspects of personality in patients with pituitary adenomas. Acta Neurochir (Wien) 1986;83:8–11.
4.
Kelly WF, Kelly MJ, Faragher B: A prospective study of psychiatric and psychological aspects of Cushing’s syndrome. Clin Endocrinol (Oxf) 1996;45:715–720.
5.
Starkman MN, Schteingart DE: Neuropsychiatric manifestations of patients with Cushing’s syndrome: relationship to cortisol and adrenocorticotropic hormone levels. Arch Intern Med 1981;141:215–219.
6.
Cohen SI: Cushing’s syndrome: a psychiatric study of 29 patients. Br J Psychiatry 1980;136:120–124.
7.
Kelly WF, Checkley SA, Bender DA: Cushing’s syndrome, tryptophan and depression. Br J Psychiatry 1980;136:125–132.
8.
Loosen PT, Chambliss B, DeBold CR, Shelton R, Orth DN: Psychiatric phenomenology in Cushing’s disease. Pharmacopsychiatry 1992;25:192–198.
9.
Sonino N, Fava GA, Raffi AR, Boscaro M, Fallo F: Clinical correlates of major depression in Cushing’s disease. Psychopathology 1998;31:302–306.
10.
Sonino N, Boscaro M, Fallo F, Fava GA: A clinical index for rating severity in Cushing’s syndrome. Psychother Psychosom 2000;69:216–220.
11.
Jeffcoate WJ, Silverstone JT, Edwards CR, Besser GM: Psychiatric manifestations of Cushing’s syndrome: response to lowering of plasma cortisol. Q J Med 1979;48:465–472.
12.
Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass JA, Besser GM: Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 1991;35:169–178.
13.
Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao C, Morange I, Picó A, Ouzounian S, Young J, Hahner S, Brue T, Allolio B, Conte-Devolx B: Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur J Endocrinol 2009;160:1003–1010.
14.
Starkman MN, Schteingart DE, Schork MA: Cushing’s syndrome after treatment: changes in cortisol and ACTH levels, and amelioration of the depressive syndrome. Psychiatry Res 1986;19:177–188.
15.
Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP: The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 1997;82:912–919.
16.
van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW, Roelfsema F, Lamberts SW, Romijn JA: Quality of life in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metab 2005;90:3279–3286.
17.
Sonino N, Fallo F, Fava G: Psychosomatic aspects of Cushing’s syndrome. Rev Endocr Metab Disord 2009; in press. DOI 10.1007/s11154-009-9123-7.
18.
Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJ, Wassenaar MJ, Middelkoop HA, Pereira AM, Romijn JA: Subtle cognitive impairments in patients with long-term cure of Cushing’s disease. J Clin Endocrinol Metab 2010;95:2699–2714.
19.
Sonino N, Bonnini S, Fallo F, Boscaro M, Fava GA: Personality characteristics and quality of life in patients treated for Cushing’s syndrome. Clin Endocrinol (Oxf) 2006;64:314–318.
20.
Dorn LD, Burgess ES, Dubbert B, et al: Psychopathology in patients with endogenous Cushing’s syndrome: ‘atypical’ or melancholic features. Clin Endocrinol (Oxf) 1995;43:433–442.
21.
Flitsch J, Spitzner S, Ludecke DK: Emotional disorders in patients with different types of pituitary adenomas and factors affecting the diagnostic process. Exp Clin Endocrinol Diabetes 2000;108:480–485.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.